Glenmark Pharma advances on receiving final ANDA for Riluzole Tablets

19 Jun 2013 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs 577.65, up by 2.55 points or 0.44 % from its previous closing of Rs. 575.10 on the BSE.

The scrip opened at Rs. 570.00 and has touched a high and low of Rs. 590.00 and Rs. 570.00 respectively. So far 35741 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 609.70 on 04-Jun-2013 and a 52 week low of Rs. 352.65 on 25-Jun-2012.

Last one week high and low of the scrip stood at Rs. 588.35 and Rs. 564.05 respectively. The current market cap of the company is Rs. 15625.18 crore.

The promoters holding in the company stood at 48.31 % while Institutions and Non-Institutions held 40.52 % and 11.18 % respectively.

Glenmark Generics Inc, USA, a subsidiary of Glenmark Generics has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA) for Riluzole Tablets, 50mg. The company will commence shipping immediately.

Riluzole is indicated for the treatment of amyotrophic lateral sclerosis. Based on IMS Health sales data for the 12 month period ending March 2013, Riluzole garnered sales of $64 million.

Glenmark’s current portfolio consists of 86 products authorized for distribution in the US marketplace and 52 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Pharma Share Price

1966.05 -19.30 (-0.97%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×